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OBJECTIVE
Little is known about arsenic and diabetes in youth. We examined the association
of arsenic with type 1 and type 2 diabetes in the SEARCH for Diabetes in Youth
Case-Control (SEARCH-CC) study. Because one-carbon metabolism can influence
arsenic metabolism, we also evaluated the potential interaction of folate and
vitamin B12 with arsenic metabolism on the odds of diabetes.
RESEARCH DESIGN AND METHODS
Six hundred eighty-eight participants <22 years of age (429 with type 1 diabetes,
85 with type 2 diabetes, and 174 control participants) were evaluated. Arsenic
species (inorganic arsenic [iAs], monomethylated arsenic [MMA], dimethylated
arsenic [DMA]), and one-carbon metabolism biomarkers (folate and vitamin B12)
were measured in plasma.We used the sum of iAs, MMA, and DMA (∑As) and the
individual species as biomarkers of arsenic concentrations and the relative pro-
portions of the species over their sum (iAs%, MMA%, DMA%) as biomarkers of
arsenic metabolism.
RESULTS
Median∑As, iAs%, MMA%, and DMA%were 83.1 ng/L, 63.4%, 10.3%, and 25.2%,
respectively. ∑As was not associated with either type of diabetes. The fully
adjusted odds ratios (95% CI), rescaled to compare a difference in levels corre-
sponding to the interquartile range of iAs%, MMA%, and DMA%, were 0.68 (0.50–
0.91), 1.33 (1.02–1.74), and 1.28 (1.01–1.63), respectively, for type 1 diabetes and
0.82 (0.48–1.39), 1.09 (0.65–1.82), and 1.17 (0.77–1.77), respectively, for type 2
diabetes. In interaction analysis, the odds ratio of type 1 diabetes by MMA% was
1.80 (1.25–2.58) and 0.98 (0.70–1.38) for participants with plasma folate levels
above and below the median (P for interaction = 0.02), respectively.
CONCLUSIONS
Low iAs% versus high MMA% and DMA% was associated with a higher odds of
type 1 diabetes, with a potential interaction by folate levels. These data support
further research on the role of arsenicmetabolism in type 1 diabetes, including the
interplay with one-carbon metabolism biomarkers.
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Increasing evidence supports the role of
environmental chemicals in diabetes de-
velopment, although most studies have
focused on adult populations, and little
information is available for type 1 dia-
betes (1). Inorganic arsenic (iAs) is a
toxicant and carcinogen that occurs nat-
urally in the environment, especially in
groundwater. Dietary sources are in-
creasingly recognized as a concern for
general populations because arsenic is
found in rice, grains, and certain juices
(2). Studies in adult populations support
the association of chronic exposure to
iAs in drinking water with diabetes, spe-
cifically type 2 diabetes (3,4). Research
in children and adolescents and in pop-
ulations exposed to arsenic mostly from
food is needed.
No epidemiological studies to our
knowledge have evaluated the associa-
tion between arsenic and type 1 diabe-
tes, which is primarily characterized by
impaired insulin secretion as a result of
an autoimmune assault on pancreatic
b-cells. No experimental animal studies
have been specifically designed to eval-
uate the role of arsenic in type 1 diabe-
tes. Several lines of evidence, however,
support the consideration of arsenic in
the pathogenesis of type 1 diabetes.
First, arsenic may impair the immune
system (5). Second, prenatal arsenic ex-
posure may alter the microbiome com-
position in early childhood, potentially
influencing arsenic metabolism and sus-
ceptibility to type 1 diabetes (6). Third,
pancreatic b-cells are recognized as a
target tissue for various arsenic species
in humans, animals, and in vitro model
systems (4,7). After exposure, iAs is
methylated in the body into monome-
thylated arsenic (MMA) and dimethy-
lated arsenic (DMA) compounds that
are excreted in the urine together with
iAs, with a half-life of 4 days (8). Arsenic
metabolism, in particular higher relative
concentrations of DMA together with
lower concentrations of MMA in the
urine, has been related to increased
prevalence and incidence of diabetes
in adults (9–11).
SEARCH for Diabetes in Youth Case-
Control (SEARCH-CC) is a two-center
study designed to characterize type 1
and type 2 diabetes and assess selected
risk factors for both diabetes types in
youth (12). To provide novel informa-
tion on the potential role of arsenic in
diabetes in children, we used biospeci-
mens collected in SEARCH-CC to measure
arsenic species in plasma and investigate
their association with type 1 and type 2
diabetes. By taking together the epidemi-
ological and experimental studies and
potential mechanisms involved, we hy-
pothesized that arsenic exposure and me-
tabolism is associated with an increased
odds of both type 1 and type 2 diabetes.
Because one-carbon metabolism nutri-
ents, such as folate and vitamin B12, are
related to arsenic metabolism (13,14) and
diabetes-related outcomes (15), we ad-
justed for and conducted an interaction
analysis of plasma folate and vitamin B12
in regressionmodels of the association be-
tween arsenic and diabetes.
RESEARCH DESIGN AND METHODS
Study Population and Case-Control
Recruitment
SEARCH is a population-based study ini-
tiated in 2000 to better understand how
diabetes develops in children and youth.
SEARCH is being conducted in five sites
across the U.S. (South Carolina, Ohio,
Colorado, California, and Washington)
and comprises .20,000 participants age
,20 years, including a wide range of racial
and ethnic groups and socioeconomic
backgrounds (16).
For the current study, we used data
from SEARCH-CC, an ancillary study con-
ducted in two of the five SEARCH sites
(four counties around Columbia, SC, and
six counties around Denver, CO). Re-
cruitment of SEARCH-CC participants
between 10 and 22 years of age oc-
curred between July 2003 and March
2006 in primary care offices. All patients
with a clinical diagnosis of type 1 and
type 2 diabetes, potential control partici-
pants, and their parents/guardians were
provided an informational brochure and
invited to complete a one-page permission
form for further contact. Control partici-
pants were concurrently recruited from
the same primary care offices, following
the rationale that all SEARCH cases arose
from health care provider offices.
The clinical diabetes type assigned by
the health care provider was recorded
as part of the case validation process
and then categorized as type 1 (combin-
ing type 1, type 1a, and type 1b) and
type 2. Other types (including gesta-
tional diabetes mellitus, hybrid type,
maturity onset of diabetes in youth, sec-
ondary diabetes, type unknown by the
reporting source, type designated as
other, and missing type) were excluded.
In a study of the full SEARCH cohort, the
provider’s diagnosis was shown to be
consistent with a classification based
on diabetes autoantibodies and esti-
mated insulin sensitivity (17). Control
participants were confirmed as not hav-
ing diabetes by fasting glucose levels ob-
tained at the SEARCH-CC study visit
(12,18).
The response rate was 53% in case
participants and 49% in control partici-
pants (12) for a total sample size of 722
participants (445 with type 1 diabetes,
91 with type 2 diabetes, and 186 control
participants). Participants were similar in
age, sex, and race/ethnicity to nonpartici-
pants (12,18). We further excluded partic-
ipants withmissing data on plasma arsenic
species concentrations (n = 7), BMI (n = 8),
parental educational level (n = 2), and vi-
tamin B12 (n = 17), resulting in a total of
688 participants for the current study
(429 with type 1 diabetes, 85 with type 2
diabetes, and 174 control participants).
Participants$18 years of age and parents
of participants,18 years of age provided
written informed consent.
Data and Sample Collection
Trained staff used a standardized protocol
to collect sociodemographic data (sex, age,
race/ethnicity, parental educational level),
conduct a physical examination (blood
pressure, height and weight to assess
BMI, waist circumference), and collect
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fasting blood and urine samples (12).
Waist circumference was measured just
above the uppermost lateral border of
the right ilium based on National Health
and Nutrition Examination Study protocol
(19). Heightwasmeasuredwith a stadiom-
eter. Weight was measured with an elec-
tronic scale. Age- and sex-specific BMI
z scores were derived on the basis of
Centers for Disease Control and Preven-
tion national standards (20). Obesity was
defined as having a BMI$95th percentile
for age and sex.
Blood samples were obtained under
conditions of metabolic stability after at
least 8 h of fasting. Specimens were pro-
cessed at the sites and shipped within
24 h to the central laboratory (North-
west Lipid Metabolism and Diabetes
Research Laboratories, University of
Washington, Seattle, WA) and stored
at ,270°C. Total folate and vitamin
B12 concentrations in plasma were an-
alyzed by using an AccuBind ELISA kit
(Monobind, Lake Forest, CA) while fol-
lowing the manufacturer’s protocol. A
reference analysis of folate was per-
formed in 50 randomly selected samples
by microbial assay (21) in the Nutrition
Obesity Core of the Nutrition Research
Institute (Kannapolis, NC).
Plasma Arsenic Determinations
In 2014, stored aliquots of 0.5 mL
plasma per participant were shipped to
the laboratory of M.St. at the University
of North Carolina where they were ana-
lyzed for arsenic species. The iAs, MMA,
and DMA concentrations were measured
in 25 mL of plasma by using hydride gen-
eration–cryotrapping inductively coupled
mass spectrometry (22). The limits of de-
tection were 0.63 ng arsenic/L for iAs and
0.05 ng arsenic/L for MMA and DMA. The
intraassay coefficients of variation were
3.6% for iAs, 3.8% for MMA, and 3.3%
for DMA. To ensure accuracy of the
analysis, a standard reference material,
Arsenic Species in Frozen Human Urine
(SRM 2669; National Institute of Standards
and Technology) diluted in deionized
water was analyzed with approximately
every other group of samples for a total
of 34 times. The average concentrations
of iAs, MMA, and DMA in SRM 2669
determined by hydride generation–
cryotrapping inductively coupled mass
spectrometry represented 90.4%, 94.5%,
and 79.6% of the certified values, respec-
tively (Supplementary Table 1). For addi-
tional quality control, SRM 2669 was
diluted in human plasma. The averaged
concentrations determined by 12 inde-
pendent analyses represented 97.1%,
98.6%, and 89.0% of the certified values
for iAs, MMA, and DMA, respectively
(Supplementary Table 2).
We used the sum of iAs, MMA, and
DMA concentrations (∑As) to assess
total arsenic exposure. The proportions
of iAs, MMA, and DMA over their sum
and multiplied by 100 (expressed as iAs
%, MMA%, and DMA%) were used as
arsenic metabolism biomarkers.
Statistical Analysis
Statistical analyses were performed
using R version 3.1.2 software (23). Dif-
ferences in characteristics between par-
ticipants with type 1 and type 2 diabetes
and control participants were deter-
mined with Mann-Whitney U test for
continuous variables and x2 test for cat-
egorical variables (Table 1). Because ar-
senic metabolism biomarkers add up
to 100%, we graphically described the
distribution of arsenic metabolism by
Table 1—Participant characteristics by diabetes status
Control (n = 174) T1D (n = 429) T2D (n = 85)
P value
control vs. T1D
P value
control vs. T2D
Age (years) 14.1 (11.9, 16.4) 14.7 (12.2, 17.5) 15.8 (13.5, 17.8) 0.060 ,0.001
Male sex 66 (37.9) 208 (48.5) 28 (32.9) 0.023 0.518
Race ,0.001 ,0.001
Non-Hispanic white 97 (55.7) 339 (79.0) 21 (24.7)
African American 48 (27.6) 43 (10.0) 52 (61.2)
Hispanic 29 (16.7) 47 (11.0) 12 (14.1)
Parental educational level 0.019 ,0.001
#12 years 87 (50.0) 168 (39.2) 67 (78.8)
.12 years 87 (50.0) 261 (60.8) 18 (21.2)
Waist circumference (cm) 76.4 (69.4, 87.6) 78.0 (69.8, 86.0) 108.8 (100.0, 120.2) 0.978 ,0.001
BMI (kg/m2) 22.2 (19.1, 26.5) 21.8 (19.1, 25.0) 34.5 (29.8, 40.1) 0.125 ,0.001
Obesity 40 (23.0) 52 (12.1) 74 (87.1) 0.001 ,0.001
Diabetes duration (years) NA 3.3 (0.9, 7.9) 1.3 (0.6, 2.0) ,0.001*
Total folate (mg/L) 19.9 (14.5, 25.2) 20.2 (15.2, 25.0) 16.0 (11.6, 22.0) 0.754 0.002
Vitamin B12 (mg/L) 555.3 (416.7, 688.7) 599.8 (485.5, 728.0) 479.6 (401.7, 607.5) ,0.001 0.019
Arsenic exposure
∑As (ng/L) 83.1 (63.8, 110.3) 81.7 (64.3, 106.7) 82.9 (62.3, 98.9) 0.665 0.521
iAs (ng/L) 50.2 (40.7, 63.05) 46.6 (36.4, 59.3) 42.9 (31.9, 55.6) 0.046 0.010
MMA (ng/L) 8.1 (4.2, 13.9) 8.9 (5.5, 15.3) 9.6 (5.2, 16.0) 0.239 0.182
DMA (ng/L) 21.0 (13.0, 30.1) 22.8 (15.4, 33.7) 23.4 (17.7, 30.5) 0.196 0.227
Arsenic metabolism
iAs% 63.4 (51.2, 74.0) 58.7 (47.7, 68.9) 58.0 (46.3, 65.6) 0.011 0.027
MMA% 10.3 (6.3, 14.9) 11.2 (7.2, 16.6) 12.7 (7.4, 17.9) 0.072 0.036
DMA% 25.2 (18.6, 33.5) 28.9 (21.0, 36.1) 29.3 (21.4, 35.7) 0.014 0.048
Data are median (interquartile range) and n (%). P values were obtained byMann-Whitney U test for continuous variables and x2 test for categorical
variables. T1D, type 1 diabetes; T2D, type 2 diabetes.*P value for the comparison between T1D and T2D.
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case-control status by using a triplot
(diagram with three axes) and com-
pared the compositional means of iAs%,
MMA%, and DMA% in participants with
type 1 and type 2 diabetes compared
with control participants (Fig. 1). We
also reported the pairwise Spearman
correlations between∑As concentrations
and each arsenic metabolism biomarker
(Supplementary Fig. 1) and graphically de-
scribed the median and interquartile
range for ∑As, iAs, MMA, DMA, iAs%,
MMA%, and DMA% across participant
subgroups (Supplementary Fig. 2). Sup-
plementary Figs. 1 and 2 represent anal-
yses conducted only among participants
without diabetes because control partic-
ipants are more likely to represent the
source population.
Odds ratios (ORs) and 95% CI compar-
ing arsenic levels for each type of diabe-
tes with control were computed by
using progressively adjusted logistic re-
gression models (Table 2). Arsenic was
modeled as log-transformed for ∑As,
iAs, MMA, and DMA concentrations
and in the original scale for arsenic
metabolism biomarkers (iAs%, MMA%,
and DMA%). Instead of reporting the re-
sults for a change in 1 log-unit (arsenic
concentrations) or in 1 unit (arsenic me-
tabolism biomarkers), the ORs (95% CI)
for type 1 or type 2 diabetes were re-
scaled for an interquartile range differ-
ence in arsenic levels (i.e., comparing
participants in the 75th vs. the 25th per-
centiles of each arsenic variable based
on the distribution among control par-
ticipants). The goal of rescaling was to
report the magnitude of the association
for a difference in exposure levels that is
relevant for the study population and to
facilitate the comparison across vari-
ables (24). Model 1 was unadjusted.
Model 2 was adjusted for age (continu-
ous), sex (male, female), BMI (continu-
ous), parental educational level (#12
years, .12 years), and race/ethnicity
(non-Hispanic white, African American,
and Hispanic). Model 3 was further ad-
justed for total folate (continuous) and
vitamin B12 (continuous). We ran addi-
tional models to assess possible nonlin-
ear relationships. First, each arsenic
variable was introduced as tertile cate-
gories, and the ORs of each type of di-
abetes were compared with arsenic
tertiles 2 and 3 to the lowest tertile
(Supplementary Table 3). The cutoffs
for the tertiles were based on the per-
centiles of probabilities tertiles 1/3 and
2/3 of each arsenic variable in control
participants. Second, we graphically es-
timated the ORs of each type of diabetes
based on restricted quadratic splines
with knots at the 10th, 50th, and 90th
percentiles of each arsenic variable dis-
tribution (Supplementary Figs. 3–6).
One-carbon metabolism plays a role
in arsenic metabolism. In an exploratory
analysis, we evaluated the potential in-
teraction of folate and vitamin B12 lev-
els with arsenic metabolism on diabetes
by including the product regression
term of each arsenic variable with cate-
gorical folate and vitamin B12 variables
in the fully adjusted model (Fig. 2).
Several sensitivity analyses were per-
formed to evaluate the consistency of
the findings. First, we adjusted the mod-
els for geographical area (South Carolina
and Colorado) (Supplementary Table 4)
with similar findings. Second, we re-
peated the analyses with the exclusion
of participants with extreme values in
arsenic variables (Supplementary Table
5). Third, because of the unbalanced
number of participants with type 1 di-
abetes and control participants, we re-
peated the analyses for a 1:1 ratio for a
total of 174 control participants and
174 participants with type 1 diabetes
(selected at random among the 429),
with similar findings (Supplementary
Table 6). Finally, given the possibility
that arsenic could contribute to type 1
and type 2 diabetes in similar ways, we
also analyzed both types of diabetes
jointly (Supplementary Table 7).
RESULTS
Participant Characteristics
Compared with control participants,
participants with type 1 diabetes were
older, more likely to be male and non-
Hispanic white with higher parental ed-
ucational level and to be leaner with
higher vitamin B12 levels. Participants
with type 2 diabetes were older, more
likely to belong to racial/ethnic minority
groups, andmore likely to be obese with
lower parental educational level and
lower plasma folate and vitamin B12
levels (Table 1). Participants with both
Figure 1—Triplot representing the compositional means for arsenic metabolism biomarkers
(iAs%, MMA%, and DMA%) in control participants and participants with type 1 diabetes (T1D)
and type 2 diabetes (T2D). The P values comparing the arsenicmetabolism biomarker compositional
means were 0.02 for T1D vs. control, 0.12 for T2D vs. control, and 0.87 for T1D vs. T2D.
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type 1 and type 2 diabetes had similar
concentrations for ∑As, MMA, and
DMA and lower concentrations for iAs
as well as lower iAs%, higher MMA%,
and higher DMA% than control partici-
pants. When considering the three arsenic
metabolism biomarkers simultaneously,
controls had higher iAs% and lower
MMA% and DMA% compared with par-
ticipants with type 1 or type 2 diabetes
(Fig. 1).
The iAs% was strongly and negatively
correlated with MMA% and DMA%
(Spearman correlations 20.65 and 20.92,
respectively), whereas the correlation be-
tween MMA% and DMA% was weak and
positive (0.36) (Supplementary Fig. 1).
∑As concentrations were similar across
participant subgroups (Supplementary
Fig. 2). For arsenic metabolism bio-
markers, we found some differences by
race/ethnicity, parental educational level,
andobesity status (Supplementary Fig. 2).
Plasma Arsenic and Odds of Diabetes
Plasma∑As concentrations were not as-
sociated with type 1 diabetes compared
with control (fully adjusted OR [95% CI]
for an interquartile range difference in
log-transformed ∑As concentrations
0.88 [0.69, 1.12]) (Table 2). The direction
of the association for the corresponding
interquartile range difference, however,
was different for the individual arsenic
species, with a significant inverse associ-
ation for iAs (0.84 [0.71, 0.99]) and non-
significant positive associations for MMA
(1.22 [0.93, 1.60]) and DMA (1.15 [0.92,
1.43]), although these associations were
significant in sensitivity analysis that ex-
cluded participants with extreme arsenic
concentrations (1.42 [1.03, 1.96] for
MMA and 1.33 [1.03, 1.72] for DMA)
(Supplementary Table 5).
For arsenic metabolism, the ORs
(95% CI) of type 1 diabetes were 0.68
(0.50, 0.91), 1.33 (1.02, 1.74), and 1.28
(1.01, 1.63) for an interquartile range
difference in iAs%, MMA%, and DMA%,
respectively (Table 2, model 3). Flexible
models based on tertiles (Supplemen-
tary Table 3) and quadratic splines
(Supplementary Figs. 3 and 4) showed
similar findings. For type 2 diabetes,
the associations with plasma arsenic
concentrations and arsenic metabolism
biomarkers were not statistically sig-
nificant but mostly in the same direc-
tion as for type 1 diabetes (Table 2 and
Supplementary Figs. 5 and 6). In analyses
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for both types of diabetes combined, we
found no interaction between any of the
arsenic variables and type of diabetes (P =
0.99 for∑As, iAs%, MMA%, and DMA%).
The fully adjusted OR (95% CI) of diabetes
combined compared with control for an
interquartile range difference in ∑As,
iAs%, MMA%, and DMA% distributions
were 0.92 (0.74, 1.15), 0.71 (0.54,
0.93), 1.33 (1.04, 1.70), and 1.23 (0.99,
1.53), respectively.
Interaction of Arsenic With Folate
and Vitamin B12
In interaction analysis, the fully adjusted
ORs (95% CI) of type 1 diabetes for an
interquartile range difference in MMA%
were 0.98 (0.70, 1.38) and 1.80 (1.25,
2.58) among participants with folate lev-
els below and above the median, re-
spectively (P for interaction = 0.02)
(Fig. 2). We also found an interaction
between MMA% and folate for both
types of diabetes combined (P for inter-
action = 0.01) (data not shown) but not
for type 2 diabetes (Fig. 2). We found no
other statistically or borderline interac-
tions between folate categories andother
arsenic measures (data not shown). No
effect modification by vitamin B12 was
observed (data not shown).
CONCLUSIONS
In children and adolescents who partic-
ipated in the SEARCH-CC study, type 1
diabetes was associated with lower
plasma iAs% and higher MMA% and
DMA%. For type 2 diabetes, the associ-
ations were in the same direction but
not statistically significant possibly be-
cause of the smaller number of cases.
In analyses with type 1 and type 2 di-
abetes combined, we found no effect
modification by type, suggesting that
the association between arsenic metab-
olism biomarkers and diabetes may be
independent of diabetes type, although
this interaction analysis may lack power
as a result of the small number of type 2
diabetes cases. The associations of ar-
senic metabolism biomarkers and dia-
betes remained after adjustment for
sociodemographic factors, BMI, and
biomarkers of one-carbon metabolism
nutrients. In interaction analyses, the
association between MMA% and type 1
diabetes was stronger for participants
with higher folate levels. Similar but non-
significant interaction between MMA%
and folate was found for type 2 diabetes.
Plasma ∑As was not associated with
either type of diabetes, although type 1
diabetes was associated with lower iAs
concentrations in multiadjusted analy-
ses and with higher MMA and DMA in
analyses that excluded arsenic outliers.
Because concentrations of ∑As or indi-
vidual arsenic species in plasma are not
established biomarkers of arsenic expo-
sure, the lack of association between
∑As and diabetes in this study does
not necessarily exclude a possible asso-
ciation for arsenic exposure assessed
with more established biomarkers,
such as arsenic species in urine. A pos-
sible explanation for lower plasma iAs
but higher MMA and DMA concentra-
tions in participants with type 1 and
maybe type 2 diabetes compared with
control participants is that plasma ar-
senic concentrations may reflect the
impact of arsenic metabolism, with
faster methylation processes (higher
MMA% and DMA%) resulting in lower
iAs concentrations.
Participants came from areas of Colo-
rado and South Carolina that surrounded
large cities, and they were most likely ex-
posed to low levels of iAs in drinkingwater
compared with other rural areas of the
U.S. (25). Themajor source of iAs exposure
in the study population was probably
through diet [rice, grains, and juices
(2,26)]. Information on the exact sources,
however, is not available.
Few studies have evaluated the
health effects of arsenic exposure in chil-
dren beyond studies of birth outcomes,
infectious diseases, and neurocognitive
outcomes (27–29). In adults, arsenic ex-
posure has been associated with diabe-
tes in populations exposed to drinking
water arsenic levels .100 mg/L (30)
and ,100 mg/L (3,11,31). Several pro-
spective studies are available. Baseline
urinary concentrations of ∑As were as-
sociated with incident diabetes in rural
Arizona (32) and Colorado (33) but not in
rural areas of the southwestern andmid-
western U.S. (9). These studies reported
no association with the individual ar-
senic species.
For arsenic metabolism, increasing
evidence suggests an association with
diabetes, although the nature and im-
plications of this relationship are not
clearly understood. For cancer and car-
diovascular disease, higher MMA% and
lower DMA% in urine have generally
been associated with a higher risk of
disease (34,35). For diabetes, however,
Figure 2—ORs and 95% CI for type 1 and type 2 diabetes by MMA% in plasma and by folate and vitamin B12 levels. ORs were obtained by comparing
the 75th vs. 25th percentiles of MMA% distribution among control participants. The 75th and 25th percentiles of MMA% distribution among control
participants were 14.9% and 6.3%, respectively. ORs were also adjusted for age (continuous), sex, BMI (continuous), parental educational level
(#12, .12 years), race/ethnicity (non-Hispanic white, African American, Hispanic), total folate levels (continuous), and/or vitamin B12 levels
(continuous). The area of each data marker is proportional to each subsample size.
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studies have shown that the relation-
ship with arsenic metabolism is in the
opposite direction, with a positive as-
sociation between higher DMA% and
diabetes in urine, including cross-sectional
evidence from Bangladesh (36) and
Mexico (11) and prospective evidence
from the U.S. (9). Experimental find-
ings support that increased DMA%
could be related to diabetes develop-
ment because the toxic trivalent form
of DMA, DMA(III), has been shown to in-
hibit insulin-stimulated glucose uptake
in cultured adipocytes (37) and as a
potent inhibitor of glucose-stimulated
insulin secretion by isolated pancreatic
islets (7).
We included folate and vitamin B12
in model adjustments and interac-
tion analyses based on evidence that
suggests a role for vitamins involved in
regulating one-carbon metabolism with
both arsenic metabolism and metabolic-
related outcomes (13–15). Although the
relationship with vitamin B12 is less
clear, the association between plasma
folate and enhanced arsenic metabolism
is well established (13,14). Clinical trials
in highly arsenic-exposed populations in
Bangladesh showed that folate supple-
mentation reduced iAs% and MMA% in
urine, reduced total arsenic and MMA
concentrations in blood, and increased
DMA% in urine (13,14). The one-carbon
metabolism cycle generates methyl
groups,which are necessary for the oxida-
tive methylation of arsenite to MMA(V)
and MMA(III) to DMA(V). Data on the re-
lationship between folate and vitamin
B12with diabetes are limited. Current ex-
perimental and epidemiological evidence
suggests that both excesses and deficien-
cies in folate may be associated with
type 2 diabetes–related outcomes (15).
Less is known about the association be-
tweenone-carbonmetabolismand type1
diabetes. The current findings suggest a
potentially complex interconnection
among one-carbon metabolism, arsenic
metabolism, and diabetes, which warrants
additional research, including experimen-
tal studies.
Strengths of this study include the
large number of type 1 diabetes cases
available, the similarity of characteris-
tics of study cases to all cases identified
in South Carolina and Colorado, the ac-
curacy of provider type using autoanti-
bodies and insulin sensitivity in themain
SEARCH study (17), and the ability to
adjust for relevant confounders, includ-
ing one-carbon metabolism nutrients.
The study has several limitations. The
number of type 2 diabetes cases was
small, and we could not evaluate the
association between arsenic and type 2
diabetes with sufficient power. Most
studies of arsenic exposure and metab-
olism measured iAs and methylated ar-
senic species in urine. Because urine
samples were not collected, we could
not compare the current findings in
plasma with those traditional measures.
Studies that measured arsenic in whole
blood found a good correlation with ar-
senic in urine (38). Arsenic measured in
blood and plasma could potentially re-
flect biologically effective dose better
than urine because it is in more direct
contact with relevant tissues (10). An-
other advantage is that concentrations
in plasma do not need to be adjusted for
urine dilution (4). Data on the repeat-
ability of arsenic concentrations in
plasma or in other biomarkers in chil-
dren exposed to low arsenic through
the diet are missing. Similar to most
epidemiologic studies, we could not
differentiate between trivalent and
pentavalent forms of arsenic species.
The ability to make this distinction
would be useful given the inverse as-
sociation between iAs concentrations
and iAs% with diabetes in the current
study and the potential role of MMA(III)
and DMA(III) to explain those findings.
Because of the cross-sectional design,
we cannot evaluate the direction of
the relationships between arsenic
measures in plasma and diabetes de-
velopment. The findings, however,
would be important even if diabetes
changed arsenic metabolism and inter-
nal dose because this would imply that
diabetes can affect susceptibility to
arsenic-related health effects, includ-
ing cancer risk.
In conclusion, we found that arsenic
metabolism, characterized by the rela-
tive proportions of iAs and methylated
arsenic species in plasma, was associ-
ated with type 1 diabetes in children
and adolescents who participated in
SEARCH-CC. In particular, low iAs% ver-
sus high MMA% and DMA% were asso-
ciated with a higher odds of type 1
diabetes. Low iAs concentrations were
also associated with a higher prevalence
of type 1 diabetes. In post hoc analy-
sis, we found an interaction between
MMA% and folate levels, with stronger
associations between MMA% and type 1
diabetes among participants with higher
folate levels in plasma. These findings
provide novel evidence that links ar-
senic and diabetes in youth and support
the need for additional research that fo-
cuses specifically on the relationship
with arsenic metabolism, including a
careful evaluation of the interplay be-
tween arsenic metabolism and one-
carbon metabolism on type 1 and type 2
diabetes development.
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